@article{baptista_protein_2022,
	title = {Protein {Interaction} {Network} for {Identifying} {Vascular} {Response} of {Metformin} ({Oral} {Antidiabetic})},
	volume = {2},
	copyright = {http://creativecommons.org/licenses/by/3.0/},
	issn = {2673-7426},
	url = {https://www.mdpi.com/2673-7426/2/2/14},
	doi = {10.3390/biomedinformatics2020014},
	abstract = {Metformin is the most used oral anti-diabetic drug in the world and consequently is commonly found in the aquatic environment. Some studies demonstrated that metformin may act as an endocrine-disrupting-chemical (EDC) in fish, although it does not have a classic EDC structure. In this sense, the aim of this work was to evaluate the potential disrupting effect of metformin in the cardiovascular system through in vitro, ex vivo, and in silico studies. For this purpose, human umbilical artery (HUA) and rat aorta artery (RAA) were used. The toxic concentrations of metformin were determined by a cytotoxicity assay and in silico simulations were performed to analyze the interactions of metformin with hormonal receptors. Our results show that metformin decreases viability of the smooth muscle cells. Moreover, metformin induces a vasorelaxant effect in rat aorta and human models by an endothelium-dependent and -independent pathways. Furthermore, docking simulations showed that metformin binds to androgen receptors (AR) and estrogen receptors (ERα and ERβ). In conclusion, the in silico assays suggested that metformin has the potential to be an endocrine disruptor, acting mainly on ERα. Further studies are needed to use metformin in pregnant women without impairing the cardiovascular health of the future generation.},
	language = {en},
	number = {2},
	urldate = {2022-05-10},
	journal = {BioMedInformatics},
	author = {Baptista, Margarida and Lorigo, Margarida and Cairrao, Elisa},
	month = jun,
	year = {2022},
	note = {Number: 2
Publisher: Multidisciplinary Digital Publishing Institute},
	keywords = {A7r5 cell line, endocrine-disrupting chemical, endothelium, human umbilical artery, metformin, molecular docking, rat aorta artery, vasorelaxation},
	pages = {217--233},
}

{"_id":"j35PJuAvkRAGRjfXQ","bibbaseid":"baptista-lorigo-cairrao-proteininteractionnetworkforidentifyingvascularresponseofmetforminoralantidiabetic-2022","author_short":["Baptista, M.","Lorigo, M.","Cairrao, E."],"bibdata":{"bibtype":"article","type":"article","title":"Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)","volume":"2","copyright":"http://creativecommons.org/licenses/by/3.0/","issn":"2673-7426","url":"https://www.mdpi.com/2673-7426/2/2/14","doi":"10.3390/biomedinformatics2020014","abstract":"Metformin is the most used oral anti-diabetic drug in the world and consequently is commonly found in the aquatic environment. Some studies demonstrated that metformin may act as an endocrine-disrupting-chemical (EDC) in fish, although it does not have a classic EDC structure. In this sense, the aim of this work was to evaluate the potential disrupting effect of metformin in the cardiovascular system through in vitro, ex vivo, and in silico studies. For this purpose, human umbilical artery (HUA) and rat aorta artery (RAA) were used. The toxic concentrations of metformin were determined by a cytotoxicity assay and in silico simulations were performed to analyze the interactions of metformin with hormonal receptors. Our results show that metformin decreases viability of the smooth muscle cells. Moreover, metformin induces a vasorelaxant effect in rat aorta and human models by an endothelium-dependent and -independent pathways. Furthermore, docking simulations showed that metformin binds to androgen receptors (AR) and estrogen receptors (ERα and ERβ). In conclusion, the in silico assays suggested that metformin has the potential to be an endocrine disruptor, acting mainly on ERα. Further studies are needed to use metformin in pregnant women without impairing the cardiovascular health of the future generation.","language":"en","number":"2","urldate":"2022-05-10","journal":"BioMedInformatics","author":[{"propositions":[],"lastnames":["Baptista"],"firstnames":["Margarida"],"suffixes":[]},{"propositions":[],"lastnames":["Lorigo"],"firstnames":["Margarida"],"suffixes":[]},{"propositions":[],"lastnames":["Cairrao"],"firstnames":["Elisa"],"suffixes":[]}],"month":"June","year":"2022","note":"Number: 2 Publisher: Multidisciplinary Digital Publishing Institute","keywords":"A7r5 cell line, endocrine-disrupting chemical, endothelium, human umbilical artery, metformin, molecular docking, rat aorta artery, vasorelaxation","pages":"217–233","bibtex":"@article{baptista_protein_2022,\n\ttitle = {Protein {Interaction} {Network} for {Identifying} {Vascular} {Response} of {Metformin} ({Oral} {Antidiabetic})},\n\tvolume = {2},\n\tcopyright = {http://creativecommons.org/licenses/by/3.0/},\n\tissn = {2673-7426},\n\turl = {https://www.mdpi.com/2673-7426/2/2/14},\n\tdoi = {10.3390/biomedinformatics2020014},\n\tabstract = {Metformin is the most used oral anti-diabetic drug in the world and consequently is commonly found in the aquatic environment. Some studies demonstrated that metformin may act as an endocrine-disrupting-chemical (EDC) in fish, although it does not have a classic EDC structure. In this sense, the aim of this work was to evaluate the potential disrupting effect of metformin in the cardiovascular system through in vitro, ex vivo, and in silico studies. For this purpose, human umbilical artery (HUA) and rat aorta artery (RAA) were used. The toxic concentrations of metformin were determined by a cytotoxicity assay and in silico simulations were performed to analyze the interactions of metformin with hormonal receptors. Our results show that metformin decreases viability of the smooth muscle cells. Moreover, metformin induces a vasorelaxant effect in rat aorta and human models by an endothelium-dependent and -independent pathways. Furthermore, docking simulations showed that metformin binds to androgen receptors (AR) and estrogen receptors (ERα and ERβ). In conclusion, the in silico assays suggested that metformin has the potential to be an endocrine disruptor, acting mainly on ERα. Further studies are needed to use metformin in pregnant women without impairing the cardiovascular health of the future generation.},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2022-05-10},\n\tjournal = {BioMedInformatics},\n\tauthor = {Baptista, Margarida and Lorigo, Margarida and Cairrao, Elisa},\n\tmonth = jun,\n\tyear = {2022},\n\tnote = {Number: 2\nPublisher: Multidisciplinary Digital Publishing Institute},\n\tkeywords = {A7r5 cell line, endocrine-disrupting chemical, endothelium, human umbilical artery, metformin, molecular docking, rat aorta artery, vasorelaxation},\n\tpages = {217--233},\n}\n\n\n\n\n\n\n\n\n\n\n\n","author_short":["Baptista, M.","Lorigo, M.","Cairrao, E."],"key":"baptista_protein_2022","id":"baptista_protein_2022","bibbaseid":"baptista-lorigo-cairrao-proteininteractionnetworkforidentifyingvascularresponseofmetforminoralantidiabetic-2022","role":"author","urls":{"Paper":"https://www.mdpi.com/2673-7426/2/2/14"},"keyword":["A7r5 cell line","endocrine-disrupting chemical","endothelium","human umbilical artery","metformin","molecular docking","rat aorta artery","vasorelaxation"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/saracatanese","dataSources":["eTsH756eicg6vxuG3","TZeKmKj6mKcyHY3tK"],"keywords":["a7r5 cell line","endocrine-disrupting chemical","endothelium","human umbilical artery","metformin","molecular docking","rat aorta artery","vasorelaxation"],"search_terms":["protein","interaction","network","identifying","vascular","response","metformin","oral","antidiabetic","baptista","lorigo","cairrao"],"title":"Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)","year":2022}